Is the Prevalence of the Factor V Leiden Mutation in Patients with Pulmonary Embolism and Deep Vein Thrombosis Really Different?

Summary

Introduction. Previous investigations have suggested a lower prevalence of the factor V Leiden mutation in patients with pulmonary embolism, as compared to patients with deep leg vein thrombosis. Methods. We studied unselected patients with pulmonary embolism, in whom we also assessed the presence of deep vein thrombosis by ultra-sonography. We assessed the prevalence of heterozygosity for the factor V Leiden mutation and compared the outcome of patients with a normal ultrasound (primary pulmonary embolism) to those with an abnormal ultrasound (combined form of venous thromboembolism). Furthermore, we performed a literature search to identify all articles regarding the prevalence of heterozygous factor V Leiden mutation in patients with primary deep vein thrombosis, primary pulmonary embolism and a combined form of venous thromboembolism. We calculated a (common) odds ratio for these 3 manifestations of venous thromboembolism, including the current findings. Results. In 92 patients with proven pulmonary embolism, 25 (27%) had also an abnormal ultrasound. In these patients, the prevalence of the factor V Leiden mutation was 24% (95% CI 9%-45%), whereas the mutation was present in 5 of 67 patients with primary pulmonary embolism (7%; 95% CI 2%-16%). The literature analysis indicated the common odds ratio for the presence of heterozygous factor V Leiden mutation in patients with primary deep vein thrombosis, primary pulmonary embolism and the combined form of venous thromboembolism to be 7.9 (95% CI 5-12), 3.5 (95% CI 2-6) and 6.8 (95% CI 3-14), respectively. Conclusion. In patients with primary pulmonary embolism the prevalence of the factor V Leiden mutation appears to be half of that reported in patients with primary deep vein thrombosis. The mechanism remains unclear.

• References

• 1 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V. et al Inherited thrombophilia: part I. Thromb Haemost 1996; 76: 651-62.
• 2 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V. et al Inherited thrombophilia: part II. Thromb Haemost 1996; 76: 824-34.
• 3 Heijboer H, Brandjes DPM, Büller HR, ten Cate JW.. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep vein thrombosis. N Engl J Med 1990; 323: 1512-6.
• 4 Koster T, Rosendaal FR, Briët E, van der Meer FJ, Colly LP, Trienekens PH. et al Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61.
• 5 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH.. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
• 6 Hirsh J, Prins MH, Samama M.. Approach to the thrombophilic patient. In Hemostasis and Thrombosis; basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) 3rd edition. Philadelphia: JB Lippincott; 1994: pp. 1543-61.
• 7 Desmarais S, de Moerloose Ph, Reber G, Minazio Ph, Perrier A, Bounameaux H.. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-5.
• 8 Manten B, Westendorp RGJ, Koster T, Reitsma PH, Rosendaal FR.. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996; 76: 510-3.
• 9 Martinelli I, Cattaneo M, Panzeri D, Mannucci PM.. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997; 77: 440-3.
• 10 Baglin TP, Brown K, Williamson D, Baker P, Luddington R.. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. Thromb Haemost 1997; 77: 1219.
• 11 Turkstra F, Kuijer PMM, van Beek JR E, Brandjes DPM, ten Cate JW, Büller HR.. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med 1997; 126: 775-81.
• 12 Voorberg J, Roelse J, Koopman R, Berends F, ten Cate JW, Mertens K. et al Association of idiopathic venous thromboembolism with single point-mutation at Arg⁵⁰⁶ of factor V. Lancet 1994; 343: 1535-6.
• 13 Andersen BS, Olsen J.. Factor V Leiden mutation in women with idiopathic pulmonary embolism. Thromb Haemost 1997; 78: 1298.
• 14 Tosetto A, Missiaglia E, Gatto E, Rodeghiero F.. The VITA project: Phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Thromb Haemost 1997; 78: 859-63.
• 15 Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM.. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
• 16 Griffin JH, Evatt B, Wideman C, Fernández JA.. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 17 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP.. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
• 18 Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH.. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
• 19 Svensson PJ, Dahlbäck B.. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 20 Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH. et al The risk of recurrent venous thromboembolism in patients with an Arg⁵⁰⁶ Õ Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
• 21 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H. et al Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 22 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH.. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
• 23 Leroy-Matheron C, Levent M, Pignon J-M, Mendona C.. The 1691 G Õ A mutation in the factor V gene: Relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996; 75: 4-10.
• 24 Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B. et al The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-8.
• 25 Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter Ch.. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
• 26 Bounameaux H, Desmarais S, Reber G, Perrier A, de Moerloose P.. Resistance to activated protein C in pateints with pulmonary embolism: Influence of cancer and associated deep vein thrombosis. Thromb Haemost 1997; Suppl 310 (abstract).
• 27 Huisman MV, Büller HR, ten Cate JW, van Royen EA, Vreeken J, Kersten M-J, et al.. Unexpected high prevalence of silent pulmonary embolism in patients with venous thrombosis. Chest 1989; 95: 498-502.
• 28 Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN. et al Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441-5.
• 29 Pacouret G, Alison D, Pottier JM, Bertrand P, Charbonnier B.. Fre-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep vein thrombosis. Arch Intern Med 1997; 157: 305-8.
• 30 Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA. et al Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983; 98: 891-9.
• 31 Kruit WHJ, de Boer AC, Sing AK, van Roon F.. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med 1991; 230: 333-9.
• 32 The Columbus investigators. Low molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
• 33 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J. et al A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl Med 1996; 334: 677-81.
• 34 Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J. et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
• 35 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R. et al A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study group. Tinzaparin ou Heparine e Standard: Evaluations dans l’Embolie Pulmonaire. N Engl J Med 1997; 337: 663-9.
• 36 van 't Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG.. Increased tissue factor-initiates prothrombin activation as a result of the Arg⁵⁰⁶ Õ Gln mutation in factor V^LEIDEN . J Biol Chem 1997; 272: 20721-9.